Immunotherapies in hematology and oncology Immuntherapien in der Hämatologie und Onkologie
Heudobler D, Herr W, Thomas S (2019)
Publication Type: Journal article, Review article
Publication year: 2019
Journal
Book Volume: 25
Pages Range: 77-82
DOI: 10.1007/s00761-019-0609-y
Abstract
Background: Modern immuno-oncology has revolutionized cancer therapy in recent years. Objective: This article provides an overview of current treatment options. Material and methods: Review of the current study situation. Results: In oncology immune checkpoint inhibitors (ICPi) in monotherapy or also in combination with other drugs have become the standard of care in many tumor entities. In the treatment of hematological neoplasms chimeric antigen receptor (CAR) T‑cells and bispecific antibodies have shown impressive response rates. Tumor vaccination represents another treatment option with high potential, but has not yet achieved broad clinical application. Conclusion: Immuno-oncology with diverse approaches has become the current standard of care in cancer treatment.
Involved external institutions
Germany (DE)How to cite
APA:
Heudobler, D., Herr, W., & Thomas, S. (2019). Immunotherapies in hematology and oncology Immuntherapien in der Hämatologie und Onkologie. Onkologe, 25, 77-82. https://doi.org/10.1007/s00761-019-0609-y
MLA:
Heudobler, Daniel, Wolfgang Herr, and Simone Thomas. "Immunotherapies in hematology and oncology Immuntherapien in der Hämatologie und Onkologie." Onkologe 25 (2019): 77-82.
BibTeX: Download